All News

Not only do a majority of older patients expect e-prescriptions, but 81% preferred e-prescriptions to paper in a study published in the Perspectives in Health Information Management.

The study evaluated data collected through a global collaboration between research institutes in the United States, India, and Africa. Study results pointed to a high rate of exposure of non-smoking teenagers to second-hand smoke, both at home and outside.

The number of cancer survivors may be on the rise, but they experience continuing issues that can impair their quality of life beyond 5 years of survival, according to a new study published in Cancer.

Advocacy groups have gone to federal court to force states to make higher payments to Medicaid providers to improve access. But a spokesman for state Medicaid officials said the courts are an inappropriate place for such disputes.

23andMe is betting its growing troves of genetic data will prove essential to drug companies, medical researchers, and even health and wellness companies.

Providers and patient advocates nationwide are deeply worried about a US Supreme Court case that they say could restrict their ability across the country to seek judicial relief from low Medicaid reimbursement rates.

The pre-clinical study by researchers at the Wellcome Trust Sanger Institute in UK point to the gene BCL11A as a possible driver of this aggressive form of breast cancer.

A new study reports on the first year of the implementation of OPTIMISTIC, an innovative program they developed and implemented to prevent unnecessary hospitalizations of nursing facility residents.

Mid-trial evaluation by an independent Data Monitoring Committee found overall survival with Opdivo (nivolumab) in the Checkmate-017 trial was significantly better than the control arm. BMS now plans to submit results to the FDA for approval of the PD-1 inhibitor in lung cancer.

Interferon-free combination therapy in hepatitis C patients who undergo liver transplantation can eliminate the virus, according to 2 studies published in Gastroenterology.

New telehealth bill signed into law in New York will bring much-needed healthcare to rural and underserved communities and require Medicaid to reimburse telehealth service costs.

The combination of 2 Medi-Cal primary care rate decreases could mean primary care providers who see a lot of Medi-Cal patients will have to scale back or stop seeing those beneficiaries.

Studies from RAND and the Urban Institute estimate that eliminating subsidies for the federally facilitated Marketplaces would increase premiums between 35% and 47% and cause at least 8.2 million people to drop coverage.

Health insurer Anthem Inc has reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.

As retailers struggle to keep up with changing shopping trends, mall operators across the US are looking to fill spaces left empty by the likes of Sears and RadioShack. There is one promising new group of tenants: walk-in medical clinics.

Cost cutting and new initiatives aimed at bringing in more patients will lead to another strong year in 2015 for for-profit hospitals. Meanwhile, their not-for-profit counterparts have been given negative outlooks by credit-rating agencies.

In comments to the House Committee on Energy and Commerce, Health Subcommittee, ASCO strongly supported the FDA's resolution to rigorously regulate laboratory-developed tests.

The study, published in the journal Cancer Prevention Research found that HPV persisted for 12 months or more in men older than 45 years of age, which could increase their susceptibility to developing head and neck cancer.

While nanotechnology has led to countless advancements, a group of Israeli researchers are now raising a flag of caution about its effects on our health. They say exposure to tiny silica-based particles can play a big role in increasing heart attack and stroke risks.

In command and ready for a fight, Republicans ignored a White House veto threat and advanced a bill in Congress that would curb President Barack Obama's healthcare overhaul by redefining full-time work as 40 hours a week.

The Consumer Financial Protection Bureau and the Kaiser Family Foundation have both examined how rising cost-sharing and the complexity of medical billing put patients at a disadvantage when they are most vulnerable. Patients tell the CFPB that bill collectors are calling even when they can't get complete information about the medical bill in question.

The FDA approved on Thursday a new anti-clotting drug to reduce the risk of stroke and dangerous blood clot in patients with non-valvular atrial fibrillation.

Research at Heildelberg University is targeting the production of tumor-promoting growth factors in endothelial cells to prevent metastasis. Pre-clinical results using this strategy in a mouse model reduced lung and bone metastases in treated mice and also improved survival over the control chemotherapy-treated animals.

A new collaboration between NCCN and Flatiron Health will provide the opportunity to analyze key quality and outcomes metrics and identify trends and patterns in the care of patients with cancer.

Following FDA approval of a DNA test to detect the HPV virus last year, the medical community is split over which test is more appropriate as a primary screen for cervical cancer in women.

If the Supreme Court invalidates Affordable Care Act subsidies for consumers on the federal exchange, states without their own Marketplaces will be unlikely to stave off "immediate destabilization" of their insurance market, according to experts.

ASCO and AACR called on the FDA to regulate e-cigarettes and other electronic nicotine delivery systems and for more research to occur to find out how long-term use affects health. Leaders of these groups said that e-cigarettes could cause nicotine addiction among teens, and CDC data show rising use of the products among middle- and high-schoolers.

Although HHS recently submitted its proposed rule for stage 3 meaningful use, which doesn't begin until 2017, the program continues to be an issue for providers and hospitals.

The study published in the New England Journal of Medicine found nearly 100% survival with adjuvant paclitaxel and trastuzumab.

The investigational drug by Sandoz, filgrastim, a biological similar to Amgen's Neupogen, is already approved for use in more than 40 countries worldwide.